Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
New Stelara Biosimilars Earn May Listing, Eylea Follow-On Takes Pass Again
Two new biosimilar versions of the anti-IL-12/23p40 antibody Stelara (ustekinumab) will join the NHI price list on May 21, along with a throng of additional dosage forms of existing products, according to the government’s official gazette issued on May 20.…
To read the full story
Related Article
- Multi-Dose Wegovy Pen Now Available in Japan: Novo
July 22, 2025
- Celltrion’s Stelara Biosimilar to Hit Shelves on July 8
July 1, 2025
- Bimzelx Now Available as Single-Injection Option: UCB Japan
May 30, 2025
- Camzyos, Tremfya, Tivdak, and More Now Available in Japan
May 22, 2025
REGULATORY
- MHLW Seeks Sponsors to Develop 8 “Drug-Loss” Products
March 2, 2026
- WG Members Urge Domestic Biologic Production as National Growth Strategy
March 2, 2026
- MHLW Clarifies Up to 12-Year Data Protection for Pediatric Development
March 2, 2026
- MHLW Issues 15 Notices Ahead of PMD Act Amendment
March 2, 2026
- Celltrion’s Eylea Biosimilar Nears Approval, but Listing Outlook Clouded
February 27, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…